文献速递乳腺外科

碳标记靶向淋巴结活检用于乳腺癌原发系统治疗后的前瞻性多中心TATTOO试验

Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial.
PubMed 文献 · Br J Surg · 2021-01-01

TATTOO试验是一项前瞻性多中心研究,纳入118例初始cT1-4c cN1-3 cM0浸润性乳腺癌患者,在原发系统治疗前向最可疑腋窝淋巴结注射碳悬浮液,治疗后行靶向淋巴结活检。110例可分析,靶向淋巴结检出率93.6%(103/110),前哨淋巴结与靶向淋巴结一致率60%,靶向联合前哨淋巴结活检(靶向腋窝清扫)的假阴性率为9%。结论认为碳标记后靶向腋窝清扫检出率高、假阴性率可接受,在资源有限环境也可行。

要点

  • 碳标记靶向淋巴结检出率93.6%(103/110),前哨与靶向淋巴结一致率60%。
  • 靶向联合前哨淋巴结活检的假阴性率为9%。
  • 该方法避免辐射暴露、高成本和术前定位操作,资源有限环境也可行。

核心结论

  • 碳标记后靶向腋窝清扫检出率高、假阴性率可接受,临床可行。

研究设计与样本

  • 前瞻性多中心试验,纳入118例初始cT1-4c cN1-3 cM0浸润性乳腺癌患者,110例可分析。

主要发现

  • 靶向淋巴结检出率为93.6%(103/110)。
  • 前哨淋巴结与靶向淋巴结一致率为60%。
  • 靶向联合前哨淋巴结活检的假阴性率为9%。

临床怎么用

  • 原发系统治疗前向最可疑腋窝淋巴结注射碳悬浮液,治疗后行靶向淋巴结活检。
  • 腋窝降期者加做前哨淋巴结活检,仍有可疑淋巴结者行腋窝淋巴结清扫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several techniques for targeted lymph node biopsy in patients with node-positive breast cancer receiving primary systemic therapy are in use, each with their inherent advantages and disadvantages. The aim of the TATTOO trial was to evaluate the feasibility and accuracy of carbon tattooing of positive lymph nodes as a method for targeted lymph node biopsy avoiding radiation exposure, high costs, and preoperative localization procedures. METHODS: Patients with initially cT1-4c cN1-3 cM0 invasive breast cancer were included in this prospective multicentre trial. Before initiation of primary systemic therapy, a carbon suspension was injected into the most suspicious axillary lymph node. Targeted lymph node biopsy was performed in all patients after completion of primary systemic therapy. Additional sentinel lymph node biopsy was done in those with axillary downstaging, and completion axillary lymph node dissection in patients still presenting with suspicious lymph nodes. RESULTS: A total of 118 patients were included and 110 were eligible for data analysis. The detection rate for the targeted lymph node was 93.6 per cent (103 of 110), and the sentinel lymph node was identical to the targeted lymph node in 60 per cent. The false-negative rate for the combination of targeted and sentinel node lymph node biopsy (targeted axillary dissection) was 9 per cent. CONCLUSION: Targeted axillary dissection after carbon tattooing is associated with a high detection rate, an acceptable false-negative rate, and appears feasible for clinical use even in healthcare settings with limited resources.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Hartmann S, Kühn T, de Boniface J, et al. Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial. Br J Surg. 2021. PMID: 33793745. doi:10.1093/bjs/znaa083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。